http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007073559-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc5b2f625569a279a31d6d92ab5106a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da215e57f9a3afa721eed529894bc40e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C11C1-00
filingDate 2006-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c9c2fb6e0669c54c8a94fc9147eb739
publicationDate 2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007073559-A3
titleOfInvention Inositolphospholipids and analogues: phosphalidylinositol products and processes
abstract Embodiments of the invention relate to natural and synthetic inositolphospholipid (EPL) materials, their preparation and applications. They provide compositions of the parent IPL comprising phosphatidylinositol (PI), PI-phosphates (phosphoinositides) and derivatives and analogues, and a process for their production starting from natural IPL. The embodiments further provide functional derivatives of PI for biomedical applications including a platform for drug design and delivery to therapeutic targets in the phosphoinositide mediated cellular signaling and allied cascades. The embodiments pertain to IPL having absolute stereo-structure. The embodiments further pertain to unique IPL and PI product compositions for defined applications, particularly pharmaceutical compositions for prophylaxis and treatment of diseases related to aberrant cellular and nuclear signaling mediated by PI and PI derived phosphates, and associated phosphoinositide specific enzymes including PI-PLC and PI 3-kinase.
priorityDate 2005-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6737536-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004191304-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4515722-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004214783-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29468
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373899
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14827
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100174305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16738692
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2923
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426228888

Total number of triples: 25.